Activin receptor‐like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes

Abstract Varieties of transforming growth factor‐β (TGF‐β) antagonists have been developed to intervene with excessive TGF‐β signalling activity in cancer. Activin receptor‐like kinase5 (ALK5) inhibitors antagonize TGF‐β signalling by blocking TGF‐β receptor‐activated Smad (R‐Smad) phosphorylation....

詳細記述

書誌詳細

主要な著者:	Jeong‐Hwan Yoon, Su Myung Jung, Seok Hee Park, Mitsuyasu Kato, Tadashi Yamashita, In‐Kyu Lee, Katsuko Sudo, Susumu Nakae, Jin Soo Han, Ok‐Hee Kim, Byung‐Chul Oh, Takayuki Sumida, Masahiko Kuroda, Ji‐Hyeon Ju, Kyeong Cheon Jung, Seong Hoe Park, Dae‐Kee Kim, Mizuko Mamura
フォーマット:	Artigo
言語:	Inglês
出版事項:	Springer Nature 2013-10-01
シリーズ:	EMBO Molecular Medicine
主題:	ALK5 inhibitor Eomes melanoma Smad4 TGF‐β
オンライン･アクセス:	https://doi.org/10.1002/emmm.201302524
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!